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How to do (or not to do). . .
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Methods of cost-effectiveness analysis (CEA) have largely been developed for application in Western
country settings. Little attention has been paid to the methodological issues in cost valuation in
resource-poor settings, where failing exchange rates and severe market distortions require further
clarifications of appropriate valuation methods. This paper links insights from social cost-benefit
analysis with the current CEA guidelines to develop a more apt approach to cost valuation in resource-
poor settings.
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Introduction
Guidelines for cost-effectiveness analysis (CEA) in
resource-poor settings generally have a clear disease focus,
covering diarrhoeal diseases (World Health Organization
1988), immunization (World Health Organization 1979),
HIV/AIDS (Pepperall et al. 1994; Kumaranayake et al.
2000), tuberculosis (Sawert 1996), or safe blood services
(World Health Organization 1998). One common feature
of all these guidelines is that they draw on costing
methods that have largely been developed for application
in Western countries, in which markets function relatively
well, and observed prices of goods often reflect economic
value (Sugden and Williams 1978; Gittinger 1984; Gold
et al. 1996; Drummond et al. 1997; Walker 2001).
However, these methods may not be readily applicable to
resource-poor settings in the presence of failing exchange
rates, trade restrictions and market distortions. In those
instances, observed prices or charges do not necessarily
reflect the economic value and need to be particularly
accounted for in cost analysis. For example, an emerging
question is the valuation of drug costs in the presence of
patents. This is especially relevant in HIV/AIDS control
now that off-patent antiretroviral drugs are becoming
available. Which drug price should be included in CEA?
Also, in the presence of import tariffs, a relevant question
is whether international or (higher) domestic prices should
be included in CEA? Furthermore, in many developing
countries, the Ministry of Health receives many inputs
free of charge or at reduced price, such as donated drugs,
radio or television time for health education and commu-
nication, or volunteer labour. What value needs to be
established for these items, considering that they could
have alternative uses?
In addition, there is little methodological guidance to
the question of how to transfer intervention cost esti-
mates from one country to another. This is especially
relevant for many developing countries which do not
have the resources available to carry out CEA for many
interventions.
This paper provides a practical approach to deal with the
above issues and draws thereby on guidelines for social
cost-benefit analysis (SCBA) (Little and Mirrlees 1969;
United Nations Industrial Development Organization
1972), as developed in the late 1960s for the evaluation
of development projects in resource-poor settings. SCBA
guidelines are grounded in the economic concepts of
‘opportunity cost’, here defined as the value foregone
by not using the same resource in the best alternative
activity, and the term ‘shadow price’ is used to reflect the
opportunity cost, or the true cost (or value) to society
(Little and Mirrlees 1969; United Nations Industrial
Development Organization 1972; Sugden and Williams
1978; MacArthur 1997). The paper also draws on the
World Health Organization manual for cost analysis
in primary care (Creese and Parker 1994). The World
Health Organization guidelines on cost-effectiveness
analysis are partly based on the findings of this present
paper (Tan-Torres Edejer et al. 2003).
A methodological framework to the valuation of costs
in a resource-poor setting is proposed in the following
section. This includes the choice of price level and
a distinction between traded and non-traded goods. The
subsequent section discusses the extrapolation of inter-
vention costs to other settings. Costs may vary because
of differences in resource prices and/or resource quan-
tities, but the focus of this paper is on the former only.
Cost valuation
Choosing the price level
In nearly all economies, domestic market price levels are
higher than world (or international) market price levels,
which may be caused by exchange controls, import quotas
and other trade restrictions. Since interventions consume
a mixture of domestically and internationally produced
goods, it is important for purposes of consistency to
define the price level (also called numeraire) against which
costs are valued. Consider, for example, a cost analysis of
a tuberculosis outreach programme, which uses a vehicle
and drugs, both imported against a tariff of, respectively,
25% and 20% (Table 1). If drug costs are valued against
international price levels, also vehicles should be valued
similarly, and any import tariff should be excluded. Or,
if both goods are valued against domestic price levels,
import tariffs should be included.
In principal, the rank ordering of projects is not affected
by the choice of international or domestic price level
(United Nations Industrial Development Organization
1972). Nevertheless, it is often argued that international
price levels are the most appropriate starting point for
analysis (Little and Mirrlees 1969; Hughes 1986), since
‘they represent the actual terms on which a country can
trade’ (Little and Mirrlees 1969), and enable compara-
bility of cost estimates between countries. The opportu-
nity costs of goods and services consumed by an
intervention can then be determined by considering the
changes in foreign exchange available to the country. The
opportunity cost for imported goods can be considered
the foreign exchange that leaves the country in order
to pay for the inputs, Similarly, the value of an input to
an intervention that is produced locally but could be
exported is the value that could have been obtained for
it on the international market.
Central to the use of international prices is that any tariffs
are excluded from the analysis. Tariffs are considered
as transfer payments from one part of society to another,
and do not consume resources but simply transfer the
power to use resources from one person to another. The
need to adjust for tariffs has different consequences for
different goods, and is further discussed in the sections
on ‘traded’ and ‘non-traded’ goods below.
In addition to the price level, the currency in which
costs are finally measured must be chosen by the analyst.
While domestic currency is most useful for local decision
makers, prices are often presented in an international
currency such as the US$ for the purpose of international
comparisons. Domestic currency can be converted into
international currency by multiplying the domestic price
by the official exchange rate (OER). The decision on
currency is independent of that of the price level.
Valuation of traded goods
A traded good is a resource that is known to be imported,
or could have been imported. Traded goods, such as
equipment, supplies and pharmaceuticals, are all com-
modities that are, or could be, available on the inter-
national market, and could be available to all countries
at an international market price. The international market
price should reflect the border price of the country under
study, which requires inclusion of cost, insurance and
freight (c.i.f.) for imported goods and free on board
(f.o.b.) for exported goods. The different elements of
c.i.f. and f.o.b. are listed in Table 2.
The reason for excluding import duties and subsidies from
the c.i.f. price is that these are transfer payments, and do
not constitute a change in resources available to society
as a whole. If the good is imported, the costs of local
transport and distribution (termed ‘domestic margin’)
should be added to the international price to approximate
the local opportunity cost because local transport and
distribution does use resources. These costs can be cal-
culated by a method developed by Lima˜o and Venables
(2001) and applied by Johns et al. (2002), who estimate
the percentage change in price of a good based on the
distance it travels, the transportation infrastructure,
Table 1. Example of calculating tuberculosis intervention costs in the presence of import tariffs in a hypothetical districta
Type of good Quantity Imported Tariff International prices Domestic prices
Price level Total costs Price level Total costs
Consumables
Drugs (regimen) 150 Yes 20% $2.0 $300 $2.4 $360
Sputum tests 300 No n.a. $0.8 $225 $1.0 $300
Equipment
Vehicleb 1 Yes 25% $1200 $1200 $1500 $1500
Personnel
Nurse (FTE) 2 No n.a. $400 $800 $500 $1000
Total $2525 $3160
aThe average import tariff in the country is 25%, so the Standard Conversion Factor¼ 1/(1þ 0.25)¼ 0.8.
bShare of the vehicle used for the intervention.
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the average GDP per capita of a country, and other
variables relating to the availability of seaports, neigh-
bouring trade partners, etc.
Price variability and product differentiation
Even when international prices are readily available to the
analyst, it is common to find that similar products sold
internationally have different prices. The correct approach
depends on the cause of the price variation.
 If the variation is due to price discrimination, where the
same product is sold to different countries at varying
prices, the price should be taken that reflects the
purchase opportunities of the country in question. This
also refers to the situation where some (large) countries
can buy cheaper drugs than others because of bulk
procurement.
 If the variation is due to product differentiation (where
products are similar but not identical), some if not all
of the price difference may be justified. This may be
purely due to quality differences, or differences in the
uses and functions of a product. The analyst should use
the price of the relevant product.
 If the variation is due to differences in international
and domestic distribution costs – either because the
distances are greater, or alternative forms of transport
are used – the international market price should be
chosen to reflect the cost to the country in question.
The price used by the analyst should also reflect the
local distribution costs as are likely to occur in the
health project under study.
Excess profits
Excess profits should be treated differently for non-traded
and traded goods. For non-traded goods, excess profits
can be considered as transfer payments when the
production and consumption of the good takes place in
the same country. In other words, no opportunity cost is
incurred with income transfers between consumers and
producers. For this reason, the market price should be
adjusted to take out the excess profits.
However, this argument does not hold for traded goods:
excess profits are part of the price of the good and
therefore contribute to the loss of foreign exchange as a
result of consumption of a traded good. The consumption
of a traded good implies that society either needs to
import the good (which costs foreign exchange) or
foregoes exporting the good (which implies foregone
earnings on foreign exchange). In both instances, the
consumption of the good reflects a real opportunity cost
to society in the sense of losing foreign currency.
The situation is more complex for patented products.
Some markets exist for the reason that they are the result
of market protection given by the patent system. Patents
are argued to be a justifiable way of encouraging new
discoveries, which is essential in the area of health and
medicine, and excess profits can be considered as a way to
offset the investment costs in new discoveries, especially
related to drugs. Central to the question of whether CEA
of interventions using patented drugs should include
these excess profits is whether a generic substitute exists
and has similar effectiveness:
(1) If a generic substitute exists and has the same
effectiveness, then this price should be used. The
logic is that CEA aims to inform decision-makers on
the efficient use of resources to produce a given
output, not including current inefficiencies or sunk
costs involved in producing that output. In some
settings it might also be useful to show how the cost-
effectiveness would alter with the use of the brand-
name substitute.
(2) If no generic product exists, or is unlikely to in the
life-time of the project, or the health programme
does not have access to it, then the price of the
patented product should be used. If a generic
product is predicted to become available later in
the life of a project, then the expected generic price
should be used after this time.
This solution reflects the buyer’s opportunities: on the one
hand, it does not stop health programmes from going
ahead where generics can be used instead of branded
products; on the other hand, it does not mistakenly
support expensive programmes where generics are not yet
available.
Price availability
Prices may be obtained at the level of the health
programme, in which case adjustments may be necessary
to account for import tariffs or subsidies. Alternatively,
one can make use of published international prices, as
available on the web (e.g. for international drug prices:
http://erc.msh.org/dmpguide). However, these prices
Table 2. Elements of cost, insurance and freight (c.i.f.) and free on
board (f.o.b.)
Item Element
C.i.f. Includes:
F.o.b. cost at point of export
Freight charges to point of import
Insurance charges
Unloading from ship to pier at port
Excludes:
Import duties and subsidies
Port charges at port of entry for taxes, handling, storage,
agents’ fees, etc.
F.o.b. Includes:
All costs to get goods on board (still in harbour of
exporting country)
Local marketing and transport costs
Local port charges including taxes, storage, loading,
fumigation, agents’ fees, etc.
Export taxes and subsidies
Project boundary price
Source: Taken from Gittinger (1984).
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normally do not take into account c.i.f. or local distri-
bution costs, which should be added.
Valuation of non-traded goods
Goods that do not fall under traded goods are termed
non-traded goods (NTG), such as labour, utilities, build-
ings and domestic transport. Non-traded goods are goods
that are domestically produced and which, by nature,
cannot be imported or exported. Non-traded goods
should be similarly valued at international prices, taking
into account distortions that exist in the domestic goods
markets: ‘only thus can we ensure that we are valuing
everything in terms of a common yardstick’ (Little and
Mirrlees 1969).
The conversion process of domestic prices to international
prices rests on the idea that all non-traded goods can be
ultimately broken down into traded goods and labour.
For example, local transport by lorry could be evaluated
in terms of driver time, road and vehicle maintenance
(non-traded), and fuel (traded). Eventually, by continuing
to break down the non-traded components, the total value
of the non-traded component will be expressed in terms
of only traded goods and labour. Next, the international
price of the traded goods components should be calcu-
lated by netting out the tariffs. To do this for many goods
and services is a considerable amount of work, and
instead a weighed average import tariff can be used to
convert domestic prices of non-traded goods into inter-
national prices. To this aim, the Asian Development Bank
produces the standard conversion factor (SCF), which is
the ratio of international to domestic price level, approxi-
mated by the weighted average import tariff (Asian
Development Bank 1997). For example, if the average
tariff is 25%, the SCF would be 0.8.
Table 1 gives an example of how to calculate intervention
costs in the presence of import tariffs, for the case of a
tuberculosis outreach programme. The impact of the tariff
on the costs of traded goods such as drugs and vehicles
is straightforward and can be accounted for directly; for
the non-traded goods such as sputum tests and personnel,
an indirect approach through the SCF is used. There is a
clear difference between domestic prices and international
prices.
Labour
Labour market prices might not reflect true opportunity
costs. To determine the economic value of labour
employed in health interventions, these prices must be
adjusted for distortions in the labour market, giving the
so-called shadow wage rates.
Scarce labour: Scare labour is typically labour which
involves skilled workers for which there is little or zero
unemployment. For this type of labour, it is recom-
mended to take prevailing market wages and fringe
benefits plus the monetary value of housing and other
allowances to give an approximation of the opportunity
cost. This may well underestimate the true opportunity
cost of skilled health workers in countries where the
private sector does not function and governments control
salaries. The opportunity cost of labour is reflected by the
salary gross of tax. Taxes are transfer payments and only
change the command over resources in society, not the
total amount of societal resources available. For that
reason, taxes should not be included as a cost, i.e. they
should be ignored. Another way of looking at it is that
gross salary equals the societal value of labour, at least at
the margin (i.e. the decision to employ a person). Fringe
benefits should also be added to estimate the opportunity
costs of labour. These include the employer’s contribu-
tions to social security, other pension plans, health and
Is the good traded or potentially tradable?
Valuation of non-traded goods
Labour Utilities, buildings & transport
– use gross salary –  adjust for monopolist power
– apply shadow wage rates
   for non-scarce, volunteer
   and expatriate labour
–  exclude transfer payments
    (subsidies)
Valuation of traded goods
Include:
– value of good on international market
– cost insurance and freight (c.i.f.) for
imported goods
– domestic margin, i.e. distribution costs
Exclude:
– transfer payments (import duties/subsidies)
– excess profits of distributors and sellers in
importing country
1. Define price level
2. Distinguish traded and non-traded goods: 
yes no
 – break into traded and non-
    traded comonents 
Figure 1. Issues to consider in cost valuation
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life insurance, and perks such as use of a car, free use
of accommodation or financial contribution to private
accommodation (Levin 1983).
An important question is what to do about the valuation
of expatriate labour employed in a country on salaries
that are much higher than those paid to people with
similar skills locally. The general answer to this question
is that it depends on whether the intervention needs this
type of labour or whether the expatriate labour could be
replaced with local labour having the same qualifications,
skills and efficiency. If for some reason the intervention
absolutely needs the expatriate labour, they should be
considered as traded goods and evaluated accordingly.
However, if the intervention would be possible with local
labour, and the goal is to evaluate whether an intervention
undertaken efficiently is worth doing, then local labour
costs should be used.
Non-scarce labour: In many countries, unskilled labour is
not scarce – there are many more people who postulate
for positions in the modern sector than posts available.
The cost to the economy of using unskilled labour in a
health intervention is the opportunity cost of net output
lost elsewhere in traditional economics, or the lost health
output that it could have produced in a more narrow
interpretation.
Where labour is drawn from rural areas and would
alternatively have been employed in agricultural produc-
tion, the opportunity cost is often taken to equal the value
of lost production. An indirect way of estimating this is to
use the rural wage rate, adjusting for seasonality. At some
times of the year this might be close to zero. Where labour
is drawn from urban areas, the economic price of labour
in the urban areas can be approximated by estimates of
annual incomes in the urban informal sector. The urban
formal sector wage rate is likely to be an overestimate,
especially where minimum wage laws apply.
Voluntary labour: Voluntary labour is, by definition, free
to an intervention. If it can be assumed that the inter-
vention will always be able to call on this volunteer
labour, it would be valued at zero cost. If not, the cost of
employing others to undertake this task should be used –
effectively this means that it would normally be valued at
the wage rate of health personnel who would normally be
employed to do the same tasks.
Patient time: Many types of health interventions – such as
rehabilitation, prevention or life-saving programmes – can
affect the ability of people to work, and through this,
the total resources available to society. In the social
welfare framework, productivity costs or gains affect the
consumption of goods and services and, therefore, social
welfare. They should be included in the analysis. In the
concept of social welfare, each unit of time would have to
be weighted according to the different impacts of each
person’s production on overall societal output, and also
according to who receives the benefit of the additional
consumption. However, no appropriate way of measuring
these welfare effects is yet available. The application of a
shadow wage rate for time at the individual patient level is
erroneous, since it does not address the impact on
economy-wide changes (e.g. in case of unemployment,
there may be no societal production losses because the
sick will be replaced by other workers). The friction costs
approach takes this into account (Koopmanschap et al.
1995), but remains silent on the question of who is
affected by the changes in production, i.e. the rich or the
poor. This is important since the marginal utility of an
additional unit of consumption is different for the two
groups. Any attempt to measure this welfare change in
monetary terms would simply introduce noise into the
calculations, so it is recommended not to include changes
in production, until a correct approach is available.
In general, time costs are unlikely to be substantial, but
for certain conditions or interventions, their exclusion
may introduce bias into the comparative estimates of cost-
effectiveness, for example where people require repeated
contacts with the system. A case in point would be
treatment for a chronic condition, such as kidney dialysis,
where the omission of time costs would undervalue the
attractiveness of home dialysis compared to a facility-
based intervention. Accordingly, where they are likely to
be substantial, the analysts should report them separately
(Drummond et al. 1997).
Utilities
Utilities includes gas, electricity, water and telephone –
services which can be both privately and publicly
provided. Whether prices charged by utility providers
reflect opportunity cost depends mainly on whether the
provider is operating as a monopolist, as a colluding
partner in an oligopolistic market (a few large providers
who can maintain high prices), or whether the market
is competitive. This can be easily determined through
a basic knowledge of the utility sector. If some degree of
competition does not exist, some downward adjustment
should be made for estimated profit margins and/or
inefficiencies of the companies.
Buildings
It could be argued that in the short-term, there are not
many alternative uses of health care facilities, and
therefore the opportunity cost of these buildings is zero
or close to zero. However, in the longer term, there are
options for alternative uses, such as use in other public
activities, or sale to the private sector. Therefore, it is not
right to give buildings used for health care a zero cost
(Levin 1983). One approach is to use the annualized value
of the building, which incorporates the replacement costs
of the building, its useful life and the opportunity costs of
the funds tied up in this asset (Creese and Parker 1994).
Another approach is to use the rental value of a similar
space in the same location which could provide the same
function, for example, a private clinic or hospital. The
rental value incorporates both the depreciation and the
opportunity costs of the asset. However, this method
is only appropriate if competitive rental markets exist,
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which is certainly not the case in the rural areas of many
of the poorest countries of the world. As a result, the
former method is recommended.
Transport
The capital costs of vehicle purchase can be treated as
traded goods. Some transport operating and maintenance
costs are also traded, such as fuel and lubricants, spare
parts etc. Others, most importantly labour time (both in
driving and maintaining vehicles), are considered as non-
traded goods. To value transport costs, all inputs should
be classified into traded and non-traded goods and be
valued appropriately. However, in some instances, this
will be difficult and a price (e.g. a bus fare) can be used to
approximate transport costs.
Transferability of unit costs across settings
Many developing countries do not have the resources
available to carry out CEA for many interventions, and
could benefit from analysis performed in other (neigh-
bouring) countries. There are many barriers to extra-
polating cost-effectiveness results from one setting to
another (Mason 1997; Bryan and Brown 1998), but
methodological guidance to overcome these barriers is
largely lacking. Intervention costs can vary between
countries because of many factors, but this section
concentrates on differences in unit costs only. Unit costs
can refer to prices of goods in the most disaggregated
form (factor prices), or to goods in aggregated form (price
of services, e.g. outpatient visits). Different approaches
are relevant for different aggregation levels of information
available.
Before detailing these approaches for adjusting unit costs
from other settings, however, it is important to note that
these adjustments do not account for possible differences
in physical resource use per unit of output. Differences
in physical resource use per unit of output may occur
for several reasons, for example, due to differences in
relative factor prices, different technologies or different
levels of production efficiency (Hutton et al. 2004).
Therefore, in adjusting only for unit costs, adjustments
to total costs may be incomplete, and therefore mislead-
ing. While accounting for these variations is not dealt
with further in this paper, awareness of such differences
by the analyst is important in order to inform whether
further adjustments are necessary beyond the unit cost
adjustments.
Input prices are available at the disaggregate level
When studies have used the ingredient approach, thus
reporting quantities and prices of all factor inputs
separately, analysts in other settings could adjust for
identified differences in these quantities and prices. For
example, if separate information is available on wages,
then the approach is to identify the wage differentials
between the source and destination countries, and adjust
by the factor identified. In order not to create additional
heavy burden on the analyst, it is recommended to take
the main categories of health care personnel, using the
average wage for each. These comparisons will give
an average adjustment factor for the labour element of
the cost.
Input prices are not available at the disaggregate level
but traded and non-traded components are known
Sometimes analysts may not have the price/cost informa-
tion for their own setting. In that case, the distinction
between traded and non-traded goods should be made,
and traded goods should be valued at their international
price as described above. The prices of non-traded goods
can vary considerably between countries when expressed
in a common currency at the official exchange rate, due
to differences in purchasing power. Purchasing power
parities (PPP) could be used to convert prices of non-
traded goods, taking into account these differences. PPP
reflects the relative value of a basket of goods in one
country compared with another: by multiplying the costs
of a non-traded good in country A by the PPP (between
country A to B), the value of the inputs in country B can
be approximated. It should be noted that the goods
included in the calculation may not reflect purchasing
power differences in all goods relevant to the intervention
under study.
Input prices are not available at the disaggregate level
and traded and non-traded components are unknown
Some unit costs might not be available in a local setting
and it would be very complicated to break them into their
traded and non-traded components. An example is the
unit cost per inpatient bed day. In these cases, PPPs could
be used to translate unit costs from another setting and
would give at least an approximation of local costs. This is
not an ideal solution because it is often very difficult to tell
from the published literature if the reported unit costs of
inpatient days include all relevant costs and have been
valued appropriately. Furthermore, if unit costs of the
base country include traded goods, then transferring the
traded good component of unit cost at PPP would lead
to an incorrect transfer of this component in the target
country. Adam et al. (2003) have made available country-
specific estimates of costs of inpatient days and outpatient
services based on a combination of PPP and econometric
techniques.
Sources of information
Official exchange rates are the simplest to collect in that
they are easily available on a daily basis in many
publications and newspapers around the world. One
issue that the analyst might face is the fluctuations in
currency markets, which may be due not only to
government controls, but also to the volatile nature of
currency markets, caused by currency speculation and
rapid changes in confidence in countries and regions. The
analyst is recommended to use the rate that best reflects
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the long-term exchange situation, which is most likely
reflected by the average exchange rate for the last year.
Purchasing power parities for countries of the
Organisation for Economic Co-operation and
Development (OECD) are available on the
internet at 5http://www1.oecd.org/std/ppp1.pdf4 and
5http://www1.oecd.org/std/ppp2.pdf4. Also, the World
Bank compares Gross Domestic Product (GDP) per
capita for all countries at both official exchange rate
and PPP values at 5http://www.worldbank.org/data/
databytopic/GNPPC.pdf4.
Conclusion
The methodological framework described in this paper
is formulated to provide a clear and practical means
of valuing opportunity cost, as well as to clarify the
appropriate approach to transfer costs across countries.
This paper has introduced important terms and concepts
for opportunity cost valuation, including the choice of
price level and currency, the standard conversion factor,
and the distinction between traded goods and non-traded
goods. These issues are particularly important where
resource-poor countries are concerned, due to the wide-
spread occurrence of failing exchange rates and markets,
volunteer labour, scarce data and the need to ‘borrow’
data from other countries.
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